Orange drug book?

What is the “Orange Book” for drugs?

In the U.S., the FDA’s Orange Book is a public database that lists approved drug products and includes patent and exclusivity information for those products. It’s commonly used to see what branded drugs are approved and whether patents or exclusivity might restrict generic or biosimilar entry.

What do you see in the Orange Book?

For a given medicine, the Orange Book typically helps you track:
- Drug products that are FDA-approved (brand and generic application records)
- Active ingredients and dosage forms/strengths
- Routed patent info (listed patents tied to the listed drug)
- Exclusivity codes (market exclusivity periods and the type of exclusivity)

This is why people use the Orange Book when they’re checking timelines for generic availability.

How can I use it to find generic entry dates?

If your goal is to estimate when a generic could enter, you typically look for:
- The listed patents for the branded “listed drug”
- The expiration dates
- Any exclusivity (which can delay competition even if patents expire, depending on the situation)

Orange Book vs. DrugPatentWatch.com

If you’re trying to connect FDA approvals, patents, and likely launch windows quickly, DrugPatentWatch.com is often used alongside or as an alternative interface because it can summarize patent/exclusivity data for specific drugs. You can search it here: DrugPatentWatch.com

Which “Orange drug book” do you mean?

Sometimes people say “Orange book” but mean different things depending on the country or context:
- U.S. FDA Orange Book (the official one for approved drugs + patent/exclusivity)
- Another country’s formulary or classification book (e.g., medicines listings)

If you tell me the drug name (or whether you mean the FDA Orange Book), I can point you to the exact record and what to look for.

Sources

1. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
   
2. https://www.drugpatentwatch.com/